X

Trial Profile

Phase 1b/2 Clinical Study on Safety, Pharmacokinetics, and Preliminary Efficacy of CEND-1 for Injection in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 06 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cerepetide (Primary) ; Gemcitabine; Paclitaxel
Indications Adenocarcinoma; Pancreatic cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Qilu Pharmaceutical

Most Recent Events

04 Sep 2024 Status changed from recruiting to completed.
14 Aug 2023 According to a Lisata Therapeutics media release, final data is expected by the end of the second quarter of 2024.
06 Jun 2023 Results (n=38; as of 30 Nov 2022) reporting safety and efficacy data presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com